Meeder Advisory Services Inc. bought a new stake in shares of CVS Health Corporation (NYSE:CVS – Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The firm bought 24,886 shares of the pharmacy operator’s stock, valued at approximately $2,574,000.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Beaird Harris Wealth Management LLC lifted its position in shares of CVS Health by 201.0% during the second quarter. Beaird Harris Wealth Management LLC now owns 292 shares of the pharmacy operator’s stock worth $30,000 after purchasing an additional 195 shares in the last quarter. J.Safra Asset Management Corp acquired a new position in CVS Health in the 2nd quarter worth $30,000. Dunhill Financial LLC purchased a new position in CVS Health in the 2nd quarter valued at about $32,000. Swiss RE Ltd. acquired a new stake in shares of CVS Health during the fourth quarter valued at about $26,000. Finally, Sankala Group LLC purchased a new stake in shares of CVS Health during the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.
Key Headlines Impacting CVS Health
Here are the key news stories impacting CVS Health this week:
- Positive Sentiment: CVS reported strong second-quarter results, with earnings per share rising more than 40% year over year as profitability in its Health Care Benefits segment improved. The company also raised its 2026 adjusted operating income outlook, reinforcing the recovery story. CVS Q2 EPS Gains From Improved Health Care Benefits Profitability
- Positive Sentiment: CVS appointed Teresa Heitsenrether, JPMorgan’s data and analytics chief, to its board. Her technology, analytics and operating experience could support CVS’s artificial-intelligence and data initiatives, potentially improving efficiency and decision-making across its businesses. CVS adds JPMorgan data executive to board amid AI push
- Positive Sentiment: Brokerages assigned CVS an average “Moderate Buy” rating, reflecting improved earnings momentum and optimism about Aetna’s performance. CVS Health Given Average Rating of Moderate Buy
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on CVS Health
CVS Health Stock Performance
Shares of CVS opened at $94.87 on Wednesday. The stock has a market capitalization of $121.33 billion, a PE ratio of 25.10, a price-to-earnings-growth ratio of 0.93 and a beta of 0.61. The business’s fifty day moving average price is $102.41 and its 200 day moving average price is $88.56. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. CVS Health Corporation has a 12-month low of $69.51 and a 12-month high of $110.68.
CVS Health (NYSE:CVS – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, beating the consensus estimate of $1.87 by $0.71. The business had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company’s quarterly revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Equities research analysts forecast that CVS Health Corporation will post 8.02 EPS for the current year.
CVS Health Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date was Thursday, July 23rd. CVS Health’s dividend payout ratio is presently 70.37%.
Insider Activity
In related news, Director Larry Robbins sold 370,462 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the transaction, the director owned 4,824,799 shares in the company, valued at $450,877,466.55. The trade was a 7.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.85% of the company’s stock.
CVS Health Profile
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
Featured Stories
- Five stocks we like better than CVS Health
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.
